What to Know Before Joining an Asthma Clinical Trial in the U.S.

Many Americans with asthma still struggle to breathe freely despite using every inhaler their doctor prescribes. Clinical trials might offer a different path forward. Asthma affects roughly 25 million people across the United States, and yet for a significant number of them, standard treatments simply do not do enough. You might recognize this feeling: the wheeze that creeps back a few hours after your last puff, the nighttime tightness that interrupts sleep, the hesitation before climbing a flight of stairs. When controller medications and rescue inhalers fail to keep symptoms at bay, the question becomes: what else is out there? Clinical trials have become a meaningful option for people stuck in that exact situation. The landscape of asthma research in the U.S. has shifted noticeably in the past couple of years. In April 2026, the FDA approved Breztri Aerosphere as the first triple-combination therapy in a single inhaler for asthma patients aged 12 and older. Around the same time, researchers at the American Thoracic Society conference presented data from the PASSAGE study, a real-world trial examining tezepelumab across diverse patient groups including Black Americans and adolescents—populations often underrepresented in asthma research. And late last year, depemokimab, a biologic given just twice a year, received approval for severe eosinophilic asthma based on trials conducted at hundreds of sites across the U.S. and beyond. These developments did not happen in a vacuum. They happened because thousands of people volunteered to participate in studies that tested whether these treatments worked and for whom. That is the engine behind every new asthma option: ordinary patients stepping into the unknown.

What the Trial Landscape Looks Like

Not all asthma trials are created equal, and understanding the differences matters before you start searching. The type of trial you encounter will depend heavily on your asthma severity, your current treatment regimen, and what researchers are trying to answer.

Some trials test biologic medications—lab-engineered antibodies that target specific inflammatory pathways. These are typically for people with moderate to severe asthma that has not responded to standard inhalers. You might be asked to receive injections every few weeks or months and visit a clinic for lung function tests and blood work. Other trials focus on inhaler formulations, comparing a new device or drug combination against what is already on the market. These can be shorter and may feel more familiar if you have been using inhalers for years.

Then there are observational studies, where no experimental treatment is given at all. Researchers simply track your symptoms, triggers, and lung function over time. You contribute data without changing your medication routine. Lifestyle intervention trials round out the picture—these explore whether changes in diet, exercise habits, or home environment can reduce asthma burden.

The table below offers a snapshot of how these trial categories compare.

Trial Category	What Researchers Study	Typical Time Commitment	Best Suited For	Potential Upside	Key Trade-Off
Biologic Medication	Targeted antibody drugs (injections)	6 to 24 months	Moderate to severe, uncontrolled asthma	Access to advanced therapies not yet widely available	Regular clinic visits; possible placebo group
Inhaler Device or Drug	New delivery systems or combination formulas	3 to 12 months	Mild to moderate asthma	Familiar treatment format; often shorter duration	May need to pause current medications
Observational Research	Disease patterns, triggers, quality of life	Varies, often 6 to 18 months	Any asthma type	No experimental drug exposure	No direct treatment benefit to you
Lifestyle Intervention	Diet, exercise, environmental modifications	3 to 12 months	Mild to moderate asthma	Non-medication approach	Requires sustained behavior change

Finding a Trial That Fits

The most direct route is ClinicalTrials.gov, a database maintained by the National Library of Medicine. You can search by condition, location, and study phase. Typing "asthma" and your city or zip code will pull up a list of actively recruiting studies. Each listing spells out the eligibility criteria—things like age range, asthma severity, current medications, and sometimes specific lung function thresholds measured by FEV1. If you are looking for asthma clinical trials near me, this is where most people start.

But a database search is only the beginning. Many people find that the real filtering happens in conversation. Marcus, a 42-year-old high school teacher in Phoenix, spent years cycling through inhaler combinations that barely kept his severe asthma in check. He discovered a trial listing on ClinicalTrials.gov but hesitated for months. "I did not want to be a guinea pig," he said. What changed his mind was a phone call with the study coordinator, who walked him through the informed consent document line by line and explained exactly what each visit would involve. He enrolled in a biologic trial and, over the following year, saw his exacerbations drop from four or five annually to just one.

Large academic medical centers—places like the University of Michigan, Mayo Clinic, Duke University, and the Icahn School of Medicine at Mount Sinai—often run multiple asthma trials simultaneously. The American Lung Association also maintains a network of Airways Clinical Research Centers across the country, including sites in Arizona, Illinois, New York, North Carolina, and Vermont. These centers frequently recruit for asthma research studies and can be a good alternative to navigating the database on your own.

What Happens After You Enroll

The process begins with an initial screening visit. Expect lung function tests, a review of your medical history, and possibly blood work or allergy testing. This is when researchers determine whether you meet the study's specific requirements. It is also your chance to ask every question on your mind: How often will I need to come in? What happens if my symptoms get worse during the trial? Can I continue seeing my regular doctor?

If you qualify, you will sign an informed consent form—a document that outlines the study's purpose, procedures, risks, and your right to withdraw at any time without penalty. This is not a contract locking you in; it is a transparency tool designed to make sure you understand what you are agreeing to.

During the active phase of the trial, you might visit the clinic anywhere from once a week to once every few months. Between visits, many studies ask participants to keep a symptom diary or use a peak flow meter at home. Some trials reimburse for travel and time, though the specifics vary by study and location. The UVA Health asthma research program in Virginia, for instance, offers compensation for screening visits, but the amount depends on the particular trial.

One thing to know upfront: some trials use a placebo control, meaning a portion of participants receive an inactive substance instead of the experimental treatment. In many asthma studies, all participants continue their standard medications while the new drug or placebo is added on top. This design helps researchers isolate the effect of the treatment being tested. You should ask during the screening process whether the study is placebo-controlled and what the odds are of receiving the placebo versus the active drug. Understanding asthma clinical trial eligibility requirements before you apply can save you time and frustration.

The NIMBLE trial, which wrapped up recently, illustrated why this matters. Researchers found that switching patients to depemokimab—a biologic administered just twice a year—produced outcomes comparable to treatments that required injections every four to eight weeks. For someone driving an hour each way to a clinic, that difference in frequency is not trivial. It is the kind of practical consideration that a trial listing alone might not convey.

Weighing the Decision

The appeal of a clinical trial is straightforward: access to treatments that are not yet available to the public, closer medical monitoring than you might get in routine care, and the chance to contribute to science that could help others with asthma. The downsides are equally real: the experimental treatment might not work for you, side effects may be unknown, and the time commitment can be substantial.

There is also the question of whether you fit the criteria at all. Many biologic asthma clinical trials require evidence of a specific type of inflammation—often measured by blood eosinophil counts—or a documented history of exacerbations despite using medium-to-high-dose inhaled corticosteroids. These are not arbitrary hurdles; they help researchers test treatments on the people most likely to benefit.

Your own pulmonologist or allergist can be a valuable sounding board. They may know about trials recruiting in your area and can help you assess whether the study design makes sense given your medical history. They can also clarify how participating might affect your current treatment plan. If you are managing severe asthma and have heard about severe asthma clinical trials exploring biologics like tezepelumab or dupilumab, your specialist can help you sort through which ones are worth pursuing.

If you decide to move forward, approach the search with patience. New trials appear on ClinicalTrials.gov regularly. Check back every few weeks. Reach out to research coordinators with your questions—they are accustomed to calls from curious patients and can give you a clearer sense of what participation would actually feel like day to day. Some organizations, including the Asthma and Allergy Foundation of America, offer educational resources that break down the clinical trial process in plain language.

Asthma research in the U.S. is moving faster than it has in decades, and the people fueling that progress are not just scientists in labs. They are patients who decided that their current treatment was not enough and went looking for something better. Whether that describes you or someone you care about, the door to clinical research is open. It just takes some homework and a willingness to ask the first question.